Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,597.32
(
-0.41%
)
US TECH 100
23,565.29
(
-0.97%
)
Dow Jones
46,049.41
(
-0.38%
)
Brent Oil
107.63
(
0.98%
)
Bitcoin
69,957.47
(
-1.80%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122797
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 117084

Thursday, 06/16/2011 12:47:35 AM

Thursday, June 16, 2011 12:47:35 AM

Post# of 257259
FDA approves Nulojix (belatacept) for prevention of kidney-transplant rejection:

http://finance.yahoo.com/news/BristolMyers-Squibb-Announces-bw-3011185617.html?x=0&.v=1

Nulojix is one of the five new drugs BMY is counting on to get over the patent cliff from Plavix and Avapro—see the prologue of #msg-47502391. Whether Nujolix will be a modest niche drug or a fairly big seller remains to be seen.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now